U.S. Markets closed
  • S&P Futures

    4,158.25
    -6.50 (-0.16%)
     
  • Dow Futures

    33,974.00
    -42.00 (-0.12%)
     
  • Nasdaq Futures

    13,901.50
    -17.75 (-0.13%)
     
  • Russell 2000 Futures

    2,228.10
    -10.30 (-0.46%)
     
  • Crude Oil

    61.07
    -0.28 (-0.46%)
     
  • Gold

    1,793.40
    +0.30 (+0.02%)
     
  • Silver

    26.58
    +0.01 (+0.02%)
     
  • EUR/USD

    1.2042
    +0.0003 (+0.0241%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3934
    +0.0002 (+0.0139%)
     
  • USD/JPY

    107.9980
    -0.0450 (-0.0416%)
     
  • BTC-USD

    53,605.83
    -2,614.28 (-4.65%)
     
  • CMC Crypto 200

    1,234.36
    -28.60 (-2.26%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,068.48
    +559.93 (+1.96%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On January 29, 2021, Dr. Reddy's issued a press release announcing the Company's financial results for the quarter and nine months ended December 31, 2020. Among other results, Dr. Reddy's posted a lower-than-expected profit for the quarter, citing the impact of "trigger based impairment charges taken on a few acquired products including gNuvaring."

On this news, Dr. Reddy's American Depositary Receipt ("ADR") price fell $4.78 per ADR, or 7.24%, to close at $61.28 per ADR on January 29, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75086